Ibrutinib-related atrial fibrillation: Therapeutic challenges.

Autor:	Kapelios CJ; 1 Department of Cardiology, Laiko General Hospital, Athens, Greece., Bonou MS; 1 Department of Cardiology, Laiko General Hospital, Athens, Greece., Diamantopoulos P; 2 First Department of Internal Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Angelopoulou MK; 3 Department of Hematology, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece., Masoura C; 1 Department of Cardiology, Laiko General Hospital, Athens, Greece., Barbetseas J; 1 Department of Cardiology, Laiko General Hospital, Athens, Greece., Viniou NA; 2 First Department of Internal Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Jazyk:	angličtina
Zdroj:	Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2019 Jul; Vol. 25 (5), pp. 1258-1260. Date of Electronic Publication: 2018 Jul 17.
DOI:	10.1177/1078155218785983
Abstrakt:	Ibrutinib is a drug used in several lymphohyperplastic diseases. Its use is associated with an increased risk of atrial fibrillation. New-onset atrial fibrillation in this setting is a true challenge as several antiarrhythmic drugs are not indicated and long-term anticoagulation has several limitations. Herein, we describe our experience in treating a 55-year-old patient receiving ibrutinib who presented with new-onset atrial fibrillation and borderline arterial pressure. Since first-line therapies, electrical cardioversion and ablation, could not be performed, rhythm control with intravenous administration of amiodarone was attempted and led to prompt sinus rhythm restoration. We discuss the therapeutic challenges related to sinus rhythm restoration and anticoagulation in this group of atrial fibrillation patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu